Nonalcoholic fatty liver disease: An agenda for clinical research

Hepatology

Volumn 35, Issue 4, 2002, Pages 746-752

  Younossi, Zobair M ^a   Diehl, Anna Mae ^b   Ong, Janus P ^a  

^a INOVA FAIRFAX HOSPITAL   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; AMIODARONE; ANTILIPEMIC AGENT; ATORVASTATIN; BETAINE; CLOFIBRATE; CORTICOSTEROID; ESTROGEN; GEMFIBROZIL; NIFEDIPINE; PERHEXILINE; SALICYLIC ACID; TAMOXIFEN; TROGLITAZONE; URSODEOXYCHOLIC ACID;

ALGORITHM; CLINICAL RESEARCH; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; FATTY LIVER; HUMAN; LIVER BIOPSY; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; STEATOSIS;

EID: 0036211568     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2002.32483     Document Type: Article

References (56)

1. Non-alcoholic steatohepatitis. Mayo Clinic experiences with a hither to unnamed disease
2. Alcohol-like liver disease in nonalcoholics. A clinical and histologic comparison with alcohol-induced liver injury
3. Clinical features and natural history of nonalcoholic steatosis syndromes
4. Non-alcoholic fatty liver disease
5. Non-alcoholic steatohepatitis: A study of 49 patients
6. Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity
7. Nonalcoholic fatty liver disease: Assessment of variability in pathologic interpretations
8. Nonalcoholic steatohepatitis: A proposal for grading and staging the histological lesions
9. Nonalcoholic steatohepatitis: Definition and pathology
10. Fatty infiltration of the liver: Analysis of prevalence, radiological and clinical features and influence on patient management
11. Prevalence of and risk factors for hepatic steatosis in northern Italy
12. Liver pathology in aircrew
13. Liver investigation in 149 asymptomatic patients with moderately elevated activities of serum aminotransferases
14. Frequency of liver disease in type 2 diabetic patients treated with oral antidiabetic agents
15. Nonalcoholic fatty liver disease: Predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese
16. High prevalence of NASH among Mexican American females with type II diabetes mellitus
17. The natural history of nonalcoholic steatohepatitis: A follow-up study of forty-two patients for up to 21 years
18. The natural history of nonalcoholic fatty liver: A follow-up study
19. Nonalcoholic steatohepatitis: An expanded clinical entity
20. Cryptogenic cirrhosis: Clinical characterization and risk factors for underlying disease
21. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis
22. Cryptogenic cirrhosis and posttransplant nonalcoholic fatty liver disease
23. Metabolic and nutritional considerations in nonalcoholic fatty liver
24. Liver and biliary ultrasonography in diabetic and non-diabetic obese women
25. Liver pathology and the metabolic syndrome X in severe obesity
26. Association of nonalcoholic fatty liver disease with insulin resistance
27. Independent predictors of liver fibrosis in patients with non-alcoholic steatohepatitis
28. Patient characteristics predicting cirrhosis in non-alcoholic steatohepatitis and death in non-alcoholic steatohepatitis
29. Etiopathogenesis of nonalcoholic steatohepatitis
30. Steatohepatitis: A tale of two "hits"?
31. Peroxisomal β-oxidation and steatohepatitis
32. Mitochondria in steatohepatitis
33. Treatment of nonalcoholic fatty liver: Present and emerging therapies
34. Non-alcoholic steatohepatitis
35. Nonalcoholic steatohepatitis in obesity: A reversible condition
36. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver
37. Effect of weight reduction on hepatic abnormalities in overweight patients
38. Liver involvement in obese children: Ultrasonography and liver enxyme levels at diagnosis and during follow up in an Italian population
39. Hepatic effects of dietary weight loss in morbidly obese subjects
40. Effect on hepatic morphology of treatment of obesity by fasting, reducing diets and small bowel bypass
41. A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis
42. Atorvastatin for the treatment of NASH
43. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: A pilot study
44. Metformin reverses fatty liver disease in obese, leptin-deficient mice
45. Metformin in nonalcoholic steatohepatitis
46. Efficacy of safety of troglitazone in the treatment of lipodystrophy syndromes
47. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis
48. Vitamin E
49. Medical uses of vitamin E
50. Vitamin E treatment on nonalcoholic steatohepatitis in children: A pilot study
51. Betaine for the treatment of nonalcoholic steatohepatitis: A promising new agent
52. Treatment of non-alcoholic steatohepatitis with N-acetylcysteine
53. Two cases from the spectrum of non-alcoholic steatohepatitis
54. Effect of ursodeoxycholic acid plus diet in patients with non-alcoholic steatohepatitis
55. Ursodeoxycholic acid in the treatment of non-alcoholic steatohepatitis: Results of a prospective clinical controlled trial
56. Lack of efficacy of urodeoxycholic acid for the treatment of liver abnormalities in obese children